Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence
Sign Up to like & getrecommendations! Published in 2019 at "Oncogene"
DOI: 10.1038/s41388-019-0894-3
Abstract: Oncogenic KIT or PDGFRA tyrosine kinase mutations are compelling therapeutic targets in most gastrointestinal stromal tumors (GISTs), and the KIT inhibitor, imatinib, is therefore standard of care for patients with metastatic GIST. However, some GISTs… read more here.
Keywords: kit independent; cyclin expression; kit; expression ... See more keywords